Form 4: Caris Life Sciences Executive Reports Stock Transaction

J. Russel Denton, Senior Vice President at Caris Life Sciences, Inc., reported a transaction involving common stock, including shares withheld for tax payments.

Summary

• J. Russel Denton, Senior Vice President, General Counsel, and Secretary of Caris Life Sciences, Inc., reported a transaction on May 15, 2026.
• The transaction involved 6,047 shares of common stock, acquired at a price of $15.25 per share.
• These shares were withheld for the payment of taxes related to the vesting and settlement of Restricted Stock Units (RSUs).
• Following this transaction, Denton beneficially owns 181,515 shares of common stock directly.
• Additionally, 9,184 shares are held indirectly through a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard administrative transaction related to executive compensation rather than a strategic decision to buy or sell significant holdings.

Positives

• The transaction indicates the settlement of Restricted Stock Units (RSUs), which is a common form of executive compensation and can suggest continued commitment from management.
• The withholding of shares for tax payment is a standard procedure and does not represent a sale of shares by the executive, preserving their ownership stake.

Negatives

• The withholding of shares for tax payment, while standard, does reduce the immediate number of shares available to the executive.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions. The settlement of RSUs is a common event for executives in the life sciences sector, reflecting compensation structures and potential tax planning.

Stakeholder Impact

• Shareholders: The transaction does not directly impact the number of shares outstanding or represent a significant change in insider ownership that would typically influence share price.

Key Dates

Keywords

Caris Life Sciences, Form 4, SEC Filing, Executive Compensation, RSU Settlement, Stock Transaction, Beneficial Ownership